Vanguard Group Inc. Trims Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Vanguard Group Inc. lessened its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 4.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,702,781 shares of the biotechnology company's stock after selling 72,916 shares during the period. Vanguard Group Inc. owned about 6.41% of AnaptysBio worth $30,582,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Ensign Peak Advisors Inc raised its stake in shares of AnaptysBio by 1.1% during the first quarter. Ensign Peak Advisors Inc now owns 45,342 shares of the biotechnology company's stock valued at $1,122,000 after acquiring an additional 510 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of AnaptysBio by 0.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 149,386 shares of the biotechnology company's stock valued at $3,251,000 after acquiring an additional 555 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of AnaptysBio by 4.5% during the second quarter. California State Teachers Retirement System now owns 23,523 shares of the biotechnology company's stock valued at $478,000 after acquiring an additional 1,003 shares in the last quarter. FMR LLC raised its stake in shares of AnaptysBio by 0.4% during the first quarter. FMR LLC now owns 292,117 shares of the biotechnology company's stock valued at $6,356,000 after acquiring an additional 1,201 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of AnaptysBio by 14.8% during the fourth quarter. Jane Street Group LLC now owns 9,647 shares of the biotechnology company's stock valued at $299,000 after acquiring an additional 1,244 shares in the last quarter.

Insider Activity

In other news, CEO Daniel Faga sold 3,000 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now directly owns 749,087 shares of the company's stock, valued at $16,045,443.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Daniel Faga sold 3,000 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now directly owns 749,087 shares of the company's stock, valued at $16,045,443.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric J. Loumeau sold 5,000 shares of the company's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares in the company, valued at $81,000. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock valued at $3,586,199 over the last ninety days. 35.50% of the stock is currently owned by insiders.

AnaptysBio Price Performance

NASDAQ ANAB traded down $2.02 on Friday, hitting $22.71. The stock had a trading volume of 347,661 shares, compared to its average volume of 314,545. The business's fifty day moving average price is $23.56 and its 200 day moving average price is $20.43. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $27.50. The stock has a market cap of $607.72 million, a price-to-earnings ratio of -3.76 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. As a group, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ANAB. Wedbush raised shares of AnaptysBio from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $20.00 to $34.00 in a research note on Tuesday, March 12th. BTIG Research began coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a "buy" rating and a $55.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Monday, April 1st. Stifel Nicolaus began coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on shares of AnaptysBio in a research note on Thursday. They issued an "overweight" rating and a $56.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $46.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.